
Vitiligo

Podcasts
Continuing Medical Education
All News
Advertisement

In a striking finding, 97% of patients who had experienced no facial repigmentation whatsoever at week 24 demonstrated measurable F-VASI improvement after 104 weeks of continuous ruxolitinib cream use.
Advertisement
Advertisement
Trending on Dermatology Times
1
Soficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe AD
2
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
3
Phase 2 Trial Supports Oral VDPHL01 for Female Pattern Hair Loss
4
Study Suggests Non-Ablative Fractional Laser Reverses Epigenetic Signatures of Skin Aging
5






























